FDA Adverse Event Injury Summary report: N

AGENT

MDR report key: 23435213 · Received October 31, 2025

Report

Report Number
2124215-2025-78400
Event Type
Injury
Date Received
October 31, 2025
Date of Event
March 25, 2025
Report Date
October 31, 2025
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
OOB
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC. BECAUSE THE PRODUCT IS UNKNOWN, WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) # AND OTHER SPECIFIC PRODUCT INFORMATION.

Description of Event or Problem · 0

IT WAS REPORTED THAT RESTENOSIS OCCURRED. ON (B)(6) 2025, THE PATIENT PRESENTED TO HOSPITAL WITH SHORTNESS OF BREATH AND CHEST PRESSURE. AT THE TIME OF EVENT, THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL WHICH WERE CONTINUED. THE PATIENT WAS DIAGNOSED WITH RECURRENT ANGINA. DIAGNOSTIC CORONARY ANGIOGRAPHY REVEALED 80% IN STENT RESTENOSIS (ISR) AT THE RIGHT CORONARY ARTERY (RCA). THE OSTIAL LESION WAS SUCCESSFULLY TREATED WITH 3.50 MM X 30 MM AND 3.00 MM X 12 MM AGENT DCB BALLOONS SUCCESSFULLY. DURING THE SAME PROCEDURE, IN STENT RESTENOSIS AT THE MID-DISTAL RCA WAS TREATED WITH A 3.50 MM X 20 MM AGENT DCB DEVICE. POST REVASCULARIZATION, THE RESIDUAL STENOSIS WAS NOTED AS 0% AND TIMI FLOW WAS 3. ON (B)(6) 2025, 70% IN-STENT RESTENOSIS AT THE MID RCA WAS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION DEVICES. POST REVASCULARIZATION, THE RESIDUAL STENOSIS WAS NOTED AS 0% AND TIMI FLOW WAS 3. THE EVENT WAS CONSIDERED TO BE RESOLVED/RECOVERED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2085605 AGENT DRUG-ELUTING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY CATHETER OOB BOSTON SCIENTIFIC CORPORATION

Patients

Seq Age Sex Outcome Treatment
1 67 YR Male Required Intervention